NCT06333652View on ClinicalTrials.gov

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

PHASE2RecruitingINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Preeclampsia

Interventions

DRUG

Ravulizumab

Intravenous infusion 100 mg/ml

Trial Locations (1)

55905

RECRUITING

Mayo Clinic Minnesota, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT06333652 - Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders | Biotech Hunter | Biotech Hunter